Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 13, 2014

View Archived Issues

Innovative Medicines Initiative launches project to develop antibiotics for Gram-negative pathogens

GSK reports approvals and developments of fourth quarter 2013

Antibody DNA barcoding used for protein analysis of fine-needle aspirates

EluSys Therapeutics presents promising results for the anthrax anti-toxin ETI-204

Researchers at Roche disclose novel modulators of neurogenesis

Dermira provides progress update for three programs

Glenmark Pharmaceuticals prepares new TRPC6 antagonists

Generex provides update on phase II AE-37 trial in breast cancer

Merck & Co. discloses novel DPP IV inhibitors

Celon Pharma patents new PDE9 inhibitors for neurodegenerative disorders

Ventrus Biosciences reports results from second phase III trial of diltiazem cream

New company Voyager Therapeutics to develop gene therapies for CNS disorders

Promising results reported for 4SC-202 in phase I trials

Pharmacyclics gains FDA approval for use of Imbruvica in new indication

Novel PADI4 inhibitors synthesized at GlaxoSmithKline

Kissei and Alteogen form business collaboration

Cabozantinib shows clinical activity in phase II trials in patients with urothelial carcinoma

Eisai to launch Pariet triple formulation combination packs for H. pylori eradication in Japan

Direct lineage reprogramming of mammalian neuronal and non-neuronal cells into neurons

FDA requests additional safety studies for DURECT's Posidur

The discovery and characterization of novel agents for the treatment of influenza

Alvogen launches biosimilar monoclonal antibody therapy in Central and Eastern Europe

FDA committee recommends against approval of cangrelor

Biodel reports preliminary results from phase I trial of concentrated insulin BIOD-531

Bayer completes decentralized registration procedure in E.U. for low-dose contraceptive patch

Sedia Biosciences receives phase II funding from NIH for HIV-1 assay

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...